boston scientific corp. - BSX

BSX

Close Chg Chg %
100.80 -1.44 -1.43%

Closed Market

99.36

-1.44 (1.43%)

Volume: 7.40M

Last Updated:

Mar 28, 2025, 3:59 PM EDT

Company Overview: boston scientific corp. - BSX

BSX Key Data

Open

$100.33

Day Range

98.04 - 100.35

52 Week Range

66.80 - 107.17

Market Cap

$149.09B

Shares Outstanding

1.48B

Public Float

1.47B

Beta

0.77

Rev. Per Employee

N/A

P/E Ratio

82.06

EPS

$1.26

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

8.16M

 

BSX Performance

1 Week
 
-1.32%
 
1 Month
 
-4.27%
 
3 Months
 
9.60%
 
1 Year
 
45.07%
 
5 Years
 
224.60%
 

BSX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 35
Full Ratings ➔

About boston scientific corp. - BSX

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

BSX At a Glance

Boston Scientific Corp.
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1234
Phone 1-508-683-4000 Revenue 16.75B
Industry Medical Specialties Net Income 1.85B
Sector Health Technology 2024 Sales Growth 17.605%
Fiscal Year-end 12 / 2025 Employees 53,000
View SEC Filings

BSX Valuation

P/E Current 82.062
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 71.622
Price to Sales Ratio 7.925
Price to Book Ratio 6.05
Price to Cash Flow Ratio 38.638
Enterprise Value to EBITDA 36.797
Enterprise Value to Sales 8.578
Total Debt to Enterprise Value 0.078

BSX Efficiency

Revenue/Employee 315,981.132
Income Per Employee 34,981.132
Receivables Turnover 6.547
Total Asset Turnover 0.449

BSX Liquidity

Current Ratio 1.081
Quick Ratio 0.642
Cash Ratio 0.082

BSX Profitability

Gross Margin 61.307
Operating Margin 15.734
Pretax Margin 13.626
Net Margin 11.071
Return on Assets 4.975
Return on Equity 9.032
Return on Total Capital 5.619
Return on Invested Capital 6.244

BSX Capital Structure

Total Debt to Total Equity 51.576
Total Debt to Total Capital 34.026
Total Debt to Total Assets 28.501
Long-Term Debt to Equity 43.036
Long-Term Debt to Total Capital 28.393
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Boston Scientific Corp. - BSX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
11.89B 12.68B 14.24B 16.75B
Sales Growth
+19.92% +6.68% +12.29% +17.61%
Cost of Goods Sold (COGS) incl D&A
4.43B 4.97B 5.41B 6.48B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.09B 1.14B 1.20B 1.27B
Depreciation
352.00M 333.00M 368.00M 413.00M
Amortization of Intangibles
741.00M 803.00M 828.00M 856.00M
COGS Growth
+2.08% +12.22% +8.88% +19.80%
Gross Income
7.46B 7.71B 8.83B 10.27B
Gross Income Growth
+33.81% +3.39% +14.48% +16.26%
Gross Profit Margin
+62.76% +60.83% +62.02% +61.31%
2021 2022 2023 2024 5-year trend
SG&A Expense
5.49B 5.84B 6.60B 7.60B
Research & Development
1.20B 1.32B 1.41B 1.61B
Other SG&A
4.29B 4.52B 5.19B 5.98B
SGA Growth
+11.36% +6.43% +13.02% +15.07%
Other Operating Expense
49.00M 47.00M 46.00M 33.00M
Unusual Expense
871.00M 417.00M 71.00M 32.00M
EBIT after Unusual Expense
1.05B 1.41B 2.11B 2.60B
Non Operating Income/Expense
374.00M 198.00M 147.00M 68.00M
Non-Operating Interest Income
4.00M 10.00M 22.00M 107.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
349.00M 464.00M 272.00M 387.00M
Interest Expense Growth
-25.43% +32.95% -41.38% +42.28%
Gross Interest Expense
349.00M 464.00M 272.00M 387.00M
Interest Capitalized
- - - -
-
Pretax Income
1.08B 1.14B 1.99B 2.28B
Pretax Income Growth
+1,462.03% +6.04% +73.97% +14.96%
Pretax Margin
+9.05% +9.00% +13.94% +13.63%
Income Tax
36.00M 443.00M 393.00M 436.00M
Income Tax - Current - Domestic
51.00M 69.00M 204.00M 342.00M
Income Tax - Current - Foreign
127.00M 381.00M 116.00M 184.00M
Income Tax - Deferred - Domestic
(259.00M) (124.00M) (104.00M) (182.00M)
Income Tax - Deferred - Foreign
117.00M 117.00M 177.00M 92.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.04B 698.00M 1.59B 1.85B
Minority Interest Expense
- - (1.00M) (8.00M)
-
Net Income
1.04B 698.00M 1.59B 1.85B
Net Income Growth
+1,368.29% -32.88% +128.22% +16.38%
Net Margin Growth
+8.75% +5.50% +11.19% +11.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.04B 698.00M 1.59B 1.85B
Preferred Dividends
- 55.00M 55.00M 23.00M
Net Income Available to Common
985.00M 642.00M 1.57B 1.85B
EPS (Basic)
0.6925 0.4488 1.0805 1.2593
EPS (Basic) Growth
+952.83% -35.19% +140.75% +16.55%
Basic Shares Outstanding
1.42B 1.43B 1.45B 1.47B
EPS (Diluted)
0.687 0.4459 1.0728 1.2471
EPS (Diluted) Growth
+946.06% -35.09% +140.59% +16.25%
Diluted Shares Outstanding
1.43B 1.44B 1.46B 1.49B
EBITDA
3.02B 2.96B 3.38B 3.90B
EBITDA Growth
+74.99% -1.82% +14.09% +15.61%
EBITDA Margin
+25.36% +23.34% +23.71% +23.31%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 119.25
Number of Ratings 35 Current Quarters Estimate 0.671
FY Report Date 03 / 2025 Current Year's Estimate 2.859
Last Quarter’s Earnings 0.70 Median PE on CY Estimate N/A
Year Ago Earnings 2.51 Next Fiscal Year Estimate 3.263
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 24 30 30
Mean Estimate 0.67 0.71 2.86 3.26
High Estimates 0.69 0.75 2.98 3.52
Low Estimate 0.66 0.68 2.83 3.16
Coefficient of Variance 1.01 2.13 0.93 2.47

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 24 25 25
OVERWEIGHT 4 4 5
HOLD 6 4 6
UNDERWEIGHT 1 1 0
SELL 0 0 0
MEAN Overweight Buy Buy

Insider Actions for Boston Scientific Corp. - BSX

Date Name Shares Transaction Value
Mar 25, 2025 Vance Ronald Brown SVP, GC and Corp. Secretary 41,019 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.85 per share 4,136,766.15
Mar 6, 2025 Emily Woodworth SVP, Global Controller and CAO 432 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.63 per share 45,200.16
Mar 6, 2025 Emily Woodworth SVP, Global Controller and CAO 2,383 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Emily Woodworth SVP, Global Controller and CAO 914 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.97 per share 95,942.58
Mar 6, 2025 Emily Woodworth SVP, Global Controller and CAO 8,063 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $37.5 per share 302,362.50
Feb 27, 2025 Joseph M. Fitzgerald EVP & Group Pres, Cardiology 5,234 Bona fide gift 0.00
Feb 27, 2025 Joseph M. Fitzgerald EVP & Group Pres, Cardiology 178,682 Bona fide gift 0.00
Feb 27, 2025 Joseph M. Fitzgerald EVP & Group Pres, Cardiology 178,342 Bona fide gift 0.00
Feb 26, 2025 Jeffrey B. Mirviss EVP&Pres, Periph Intervent 28,454 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.25 per share 2,966,329.50
Feb 26, 2025 Jeffrey B. Mirviss EVP&Pres, Periph Intervent 25,766 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104 per share 2,679,664.00
Feb 20, 2025 Daniel J. Brennan EVP and CFO 268,016 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.26 per share 4,625,956.16
Feb 20, 2025 Daniel J. Brennan EVP and CFO 31,285 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Daniel J. Brennan EVP and CFO 247,248 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.08 per share 25,733,571.84
Feb 20, 2025 Daniel J. Brennan EVP and CFO 283,658 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $27.09 per share 7,684,295.22
Feb 20, 2025 Daniel J. Brennan EVP and CFO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 John Bradley Sorenson EVP, Global Operations 20,991 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $105.19 per share 2,208,043.29
Feb 20, 2025 John Bradley Sorenson EVP, Global Operations 24,294 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.41 per share 2,536,536.54
Feb 20, 2025 Daniel J. Brennan EVP and CFO 37,067 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Daniel J. Brennan EVP and CFO 232,618 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.67 per share 24,348,126.06
Feb 20, 2025 Daniel J. Brennan EVP and CFO 251,151 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.55 per share 6,165,757.05

Boston Scientific Corp. in the News